Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose
Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose
周日报道，爱瑞诺公司报告了核瑞斯兰(ALN-TTRsc04)中期1期结果，显示单剂后TTR迅速而持久的降低，持续六个月。
- Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months
- At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 −
- Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis −
- Encouraging Safety and Tolerability Observed −
- Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –
- 单剂量Nucresiran 300毫克或更高导致15天内平均TTR水平迅速下降超过90%，并在六个月内保持稳定
- 在这些剂量下，平均TTR水平的峰值下降超过96%在第29天达到
- 数据支持每半年或每年皮下注射，代表ATTR淀粉样蛋白病治疗的新范例
- 观察到令人鼓舞的安全性和耐受性
- Alnylam继续预计在2025年第一季度分享第3阶段开发计划
资讯热榜
更新时间